会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 71. 发明授权
    • Single-crystalline organic carboxylic acid metal complex, process for producing the same, and use thereof
    • 单晶有机羧酸金属络合物,其制造方法及其用途
    • US08034165B2
    • 2011-10-11
    • US11921681
    • 2006-05-10
    • Satoshi Takamizawa
    • Satoshi Takamizawa
    • B01D53/02
    • B01D69/142B01D69/122B01J20/223C01B3/0015C07F1/005C08G73/0633C08G79/14C30B7/00C30B7/14C30B29/54C30B29/58Y02E60/328
    • A large single crystal of a complex such as an organic carboxylic acid metal complex, which crystal is useful as an adsorbent of various gases and vapors of organic solvents and as a hydrogen-absorbing material, as well as a process for producing the crystal, is disclosed. Two layers wherein an upper layer thereof is constituted by a solution containing a metal salt and an organic carboxylic acid having a conjugated system, or a solution containing a metal salt of the organic carboxylic acid having a conjugated system, and wherein a lower layer of the two layers is constituted by a solvent which is not miscible with the solvent of the solution, is formed. Vapor of pyrazine or a substituted pyrazine from a solution of pyrazine or the substituted pyrazine is introduced into the upper layer to allow reaction, thereby forming a large single crystal(s) of the organic carboxylic acid metal complex at the interface between the two layers, which crystal(s) has(have) a longer side with a size of not less than 0.8 mm.
    • 诸如有机羧酸金属络合物的复合物的大单晶,其可用作各种气体和有机溶剂的蒸气和吸收吸收材料的吸附剂,以及制备晶体的方法是 披露 两层,其上层由含有金属盐和具有共轭体系的有机羧酸的溶液构成,或含有具有共轭体系的有机羧酸的金属盐的溶液,其中, 形成两层由不溶于溶剂的溶剂的溶剂构成。 将吡嗪或取代的吡嗪的吡嗪或取代的吡嗪的蒸气引入上层以允许反应,从而在两层之间的界面处形成大的单晶有机羧酸金属络合物, 哪个晶体具有尺寸不小于0.8mm的长边。
    • 76. 发明授权
    • Preparation for prevention and healing of inflammation affections
    • US06610284B1
    • 2003-08-26
    • US09555626
    • 2000-07-27
    • Ji{haeck over (r)}í LabskýJi{haeck over (r)}í VacíkPavel Ho{haeck over (s)}ek
    • Ji{haeck over (r)}í LabskýJi{haeck over (r)}í VacíkPavel Ho{haeck over (s)}ek
    • A61K3174
    • C08G73/0672A61K31/785A61K31/787A61K31/79C08G73/0213C08G73/0627C08G73/0633
    • A preparation for prevention and healing of inflammation affections comprising in an amount of 0.1 to 99.9% by weight derivatives of sterically hindered amines selected from the group consisting of: soluble polymers or copolymers prepared by radical polymerization in the presence of 0.01 to 10% by weight, of initiators prepared:in a polymerization mixture comprising individually or in combination an aliphatic amine monomer of the general formula (A), soluble polymers or copolymers prepared by radical polymerization in the presence of 0.01 to 10% by weight of initiators from monomers of cyclic sterically hindered amines of the general formula (B), soluble polymers prepared by polycondensation of difunctional sterically hindered amines of the general formula (F), soluble polymers or copolymers prepared by polycondensation of difunctional cyclic sterically hindered amines of the general formula (G), soluble copolymers prepared by polycondensation of difunctional cyclic, sterically hindered amines of the general formula (G) and monofunctional cyclic sterically hindered amines in an amount of 0.1 to 15%. by weight, based on the total polymerization mixture, of the general formula (H), derivatives of sterically hindered cyclic amines of the general formula (O), polymers, copolymers, or natural compounds comprising free reactive groups —OH, —NH2, —COOH, —CHO, oxiranyl, selected from the group poly(vinyl alcohol), cellulose, (2-hydroxyethyl)cellulose, (carboxymethyl)celullose, agar derivatives, polymers obtained by condensation, using alkanediol derivatives, oligomers and polymers of ethylene glycol or propylene glycol, natural or synthetic polymers, comprising a free carboxyl group, amino group or aldehyde group, prepared by additional functionalization of polymers or natural compounds by polymeranalogous reaction with a suitable sterically hindered amine.